Research & Publications

Translational research has always been the linchpin of Lifedoc’s clinical framework, further enabling us to provide healthcare that is quality-oriented and data-driven. Over the last 15 years, research has remained an integral part of our efforts to maximize the applicability of health data. With active participation in industry-sponsored and investigator-initiated research, we aim to to inform emerging treatments and continually refine our clinical model for the ultimate benefit of the patient. This focus allows us to continually develop data to support our evidence-based approach, ensuring that our patients receive the most effective healthcare and clinical interventions. Ultimately, this allows us to fulfill our mission of establishing Lifedoc as a reference model for researchers and practitioners studying the development and prevention of cardiometabolic conditions.

Take a look at our past and ongoing trials, research partnerships as well as some of our published/presented studies below.

Interested in working with our research site? Contact us.

Quality care for all. A kid playing doctor.

Research Partnerships

Novo Nordisk

Industry-sponsored Clinical Trials

Ongoing Trials

– Boehringer-Ingleheim – Safety and Efficacy of SGLT-2 and DPP-4 in Type 2 Diabetes, Children 10 – 17 years of age.

Past Trials

– Janssen – Safety and Efficacy of SGLT-2  in Type 2 Diabetes, Adults – Recognized as Highest Recruiting/Retaining Site in the US

– Novo Nordisk – Safety and Efficacy of Liraglutide in Overweight and Obesity, Children and Adolescents 10-17 years of age – Recruited First and Second Patient Globally

–  Novo Nordisk – Safety and Efficacy of Liraglutide and Metformin in Type 2 Diabetes, Children and Adolescents 10-17 years of age – Recognized as Highest Recruiting Site in the US

Notable Publications

Metabolic syndrome: from global epidemiology to individualized medicine

Published: Clinical Pharmacology & Therapeutics
Date:
Authors: J A Batsis 1 , R E Nieto-Martinez, F Lopez-Jimenez
Abstract:
The metabolic syndrome (MetS) encompasses a constellation of metabolic abnormalities that are thought to place patients at higher risk for the development of diabetes and cardiovascular (CV) disease.

Obesity and cardiometabolic syndrome in children

Published: Therapeutic Advances in Cardiovascular Disease
Date:
Authors: Pedro Velasquez-Mieyer 1 , Claudia P Neira, Ramfis Nieto, Patricia A Cowan
Abstract:
The cardiometabolic syndrome is highly prevalent among overweight youth. The risk of developing the cardiometabolic syndrome is likely triggered or exacerbated by concurrent obesity, unhealthy lifestyle/eating habits, and hormonal changes (puberty).

Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents

Published: Journal of the American Academy of Nurse Practitioners
Date:
Authors: Kelly A Harden 1, Patricia A Cowan, Pedro Velasquez-Mieyer, Susan B Patton
Abstract:
The purposes of this study are threefold: to determine what components of the metabolic syndrome are present in obese adolescents, to determine what differences exist in the effects of lifestyle intervention versus lifestyle intervention plus metformin on weight management and select markers of metabolic syndrome in obese adolescents, and to determine which factors predict weight loss in obese adolescents treated with lifestyle changes and metformin.

A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion

Published: International Journal of Obesity
Date:
Authors: R H Lustig 1 , F Greenway, P Velasquez-Mieyer, D Heimburger, D Schumacher, D Smith, W Smith, N Soler, G Warsi, W Berg, J Maloney, J Benedetto, W Zhu, J Hohneker
Abstract:
To compare changes in weight in obese patients who received long-acting octreotide (octreotide LAR) at one of three dose levels (20, 40, or 60 mg) or placebo over 6 months and to identify the lowest dose of octreotide LAR that safely achieved optimal weight loss.

A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion

Published: International Journal of Obesity
Date:
Authors: R H Lustig 1 , F Greenway, P Velasquez-Mieyer, D Heimburger, D Schumacher, D Smith, W Smith, N Soler, G Warsi, W Berg, J Maloney, J Benedetto, W Zhu, J Hohneker
Abstract:
Objective: To compare changes in weight in obese patients who received long-acting octreotide (octreotide LAR) at one of three dose levels (20, 40, or 60 mg) or placebo over 6 months and to identify the lowest dose of octreotide LAR that safely achieved optimal weight loss.
1 … 8 9 10 11 12

Contact Us